Eisai, Bial Announce Partnership Agreement for Anti-Epileptic Zebinix

Eisai Europe Ltd, the European subsidiary of Eisai Co., Ltd., and Bial-Portela & CA, S.A., announced the signing of a licence and co-promotion agreement in which Eisai receives a sole license to market, promote and distribute the novel once daily anti-epileptic Zebinix (eslicarbazepine acetate) within Europe.
MarketWatch